Baseline characteristics of patients with multiple myeloma
| Characteristics . | Multiple myeloma (n = 126) . |
|---|---|
| Age (y)* | 55 (range, 33-71) |
| Sex (%) | |
| Male | 65 |
| Female | 35 |
| Disease status at transplantation (%) | |
| Plateau response | 13.5 |
| Relapsed on chemotherapy | 33.3 |
| Relapsed off chemotherapy | 38.1 |
| Primary chemorefractory | 15.1 |
| Prognostic factors for MM (%) | |
| Plasma cell labeling index 1% | 37 |
| β2-microglobulin (> 2.7 mg/L) | 59.5 |
| LDH level > normal for age/sex | 85.2 |
| Cytogenetics | |
| Normal | 64.2 |
| Abnormal | 35.8 |
| C-reactive protein level > 0.8 mg/dL | 30.3 |
| Stem cell source (%) | |
| BM | 20 |
| PBSCs | 80 |
| Platelet level > 20 × 109/L (%) | 81 |
| ALC at day 15 after ASCT (%) | |
| ≥ 500 cells/μL | 50 |
| < 500 cells/μL | 50 |
| ANC at day 15 after ASCT (%) | |
| ≥ 500 cells/μL | 95.7 |
| < 500 cells/μL | 4.3 |
| Characteristics . | Multiple myeloma (n = 126) . |
|---|---|
| Age (y)* | 55 (range, 33-71) |
| Sex (%) | |
| Male | 65 |
| Female | 35 |
| Disease status at transplantation (%) | |
| Plateau response | 13.5 |
| Relapsed on chemotherapy | 33.3 |
| Relapsed off chemotherapy | 38.1 |
| Primary chemorefractory | 15.1 |
| Prognostic factors for MM (%) | |
| Plasma cell labeling index 1% | 37 |
| β2-microglobulin (> 2.7 mg/L) | 59.5 |
| LDH level > normal for age/sex | 85.2 |
| Cytogenetics | |
| Normal | 64.2 |
| Abnormal | 35.8 |
| C-reactive protein level > 0.8 mg/dL | 30.3 |
| Stem cell source (%) | |
| BM | 20 |
| PBSCs | 80 |
| Platelet level > 20 × 109/L (%) | 81 |
| ALC at day 15 after ASCT (%) | |
| ≥ 500 cells/μL | 50 |
| < 500 cells/μL | 50 |
| ANC at day 15 after ASCT (%) | |
| ≥ 500 cells/μL | 95.7 |
| < 500 cells/μL | 4.3 |
MM indicates multiple myeloma; LDH, lactate dehydrogenase; BM, bone marrow; PBSC, peripheral blood stem cell; ALC, absolute lymphocyte count; ASCT, autologous stem cell transplantation; ANC, absolute neutrophil count.
Years expressed as the median of the group.